Celcuity (Celcuity) Debt-to-Asset : 0.20 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Celcuity Debt-to-Asset?

Celcuity's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.18 Mil. Celcuity's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $37.75 Mil. Celcuity's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $188.18 Mil. Celcuity's debt to asset for the quarter that ended in Mar. 2024 was 0.20.

Celcuity Debt-to-Asset Historical Data

The historical data trend for Celcuity's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity Debt-to-Asset Chart

Celcuity Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.02

0.17

0.20

Celcuity Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.22	0.24	0.26	0.20	0.20

Competitive Comparison of Celcuity's Debt-to-Asset

For the Biotechnology subindustry, Celcuity's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celcuity's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Celcuity's Debt-to-Asset falls into.

Celcuity Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Celcuity's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.185	+	37.261)	/	191.219
	=	0.20

Celcuity's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.182	+	37.748)	/	188.181
	=	0.20

Celcuity (NAS:CELC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Celcuity Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Celcuity's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Celcuity (Celcuity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446

Website

https://www.celcuity.com

Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).

Executives

Richard E Buller	director	C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey	director	C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht	director	C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan	director, 10 percent owner, officer: Chief Executive Officer	16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon	director	CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing	director, 10 percent owner, officer: Chief Science Officer, VP	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne	officer: Chief Financial Officer	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin	director	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446